Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...
Patients with acne vulgaris who received systemic therapies had greater rates of treatment adherence and satisfaction than with topical therapies.
Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results